280 related articles for article (PubMed ID: 18024870)
1. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
Tsao MS; Aviel-Ronen S; Ding K; Lau D; Liu N; Sakurada A; Whitehead M; Zhu CQ; Livingston R; Johnson DH; Rigas J; Seymour L; Winton T; Shepherd FA
J Clin Oncol; 2007 Nov; 25(33):5240-7. PubMed ID: 18024870
[TBL] [Abstract][Full Text] [Related]
2. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
3. [The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].
Hirai Y; Shimizu Y; Oura S; Yoshimasu T; Ota F; Nakamura R; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
Gan To Kagaku Ryoho; 2012 Mar; 39(3):381-4. PubMed ID: 22421763
[TBL] [Abstract][Full Text] [Related]
4. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
[TBL] [Abstract][Full Text] [Related]
6. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
7. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Butts CA; Ding K; Seymour L; Twumasi-Ankrah P; Graham B; Gandara D; Johnson DH; Kesler KA; Green M; Vincent M; Cormier Y; Goss G; Findlay B; Johnston M; Tsao MS; Shepherd FA
J Clin Oncol; 2010 Jan; 28(1):29-34. PubMed ID: 19933915
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Zhu CQ; Ding K; Strumpf D; Weir BA; Meyerson M; Pennell N; Thomas RK; Naoki K; Ladd-Acosta C; Liu N; Pintilie M; Der S; Seymour L; Jurisica I; Shepherd FA; Tsao MS
J Clin Oncol; 2010 Oct; 28(29):4417-24. PubMed ID: 20823422
[TBL] [Abstract][Full Text] [Related]
10. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
11. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871.
Carbone DP; Mitsudomi T; Chiba I; Piantadosi S; Rusch V; Nowak JA; McIntire D; Slamon D; Gazdar A; Minna J
Chest; 1994 Dec; 106(6 Suppl):377S-381S. PubMed ID: 7988268
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
[TBL] [Abstract][Full Text] [Related]
15. Do molecular markers predict survival in non-small-cell lung cancer?
Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
18. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
[TBL] [Abstract][Full Text] [Related]
19. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
20. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
Ikeda N; Nagase S; Ohira T
Ann Thorac Cardiovasc Surg; 2009 Jun; 15(3):144-9. PubMed ID: 19597387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]